Clinical trial · Observational
B-Cell Reconstitution After Hematopoietic Stem Cell Transplantation
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative treatment for a variety of hematological malignancies. However, patients who have received this treatment have a persistent deficit in humoral immunity up to one year post-transplant. To date, the design of new therapeutic strategies to improve immune recovery in allo-HSCT patients is still hampered by the fact that post-transplant regenerative hematopoiesis has never been studied, and more generally by our currently limited knowledge on the development and function of human B lymphocytes. The main objective of our study is to study early B-cell progenitor reconstitution after allogeneic hematopoietic stem cell transplantation.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hematologic Malignancy | Hematopoietic and Lymphoid Cell Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- B cells reconstitution
- timeFrame
- at day 100 days post-transplant
- description
- B cell clusters as assess by CyTOF technology
Secondary outcomes (3)
- measure
- B cells reconstitution
- timeFrame
- at 6 months post-transplant
- description
- B cell clusters as assess by CyTOF technology
- measure
- Perturbations in growth or differentiation of progenitor/precursor of B cells
- timeFrame
- at 100 days post transplant
- description
- Perturbations in growth or differentiation of progenitor/precursor of B cells will be assessed by cytometry technology
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Patients : * 18 years of age and older * with hematological malignancies and subject to allogeneic HSCT * with health insurance coverage (bénéficiaire ou ayant droit) * having signed a written informed consent. Inclusion criteria of donor * 18 years of age and older * with health insurance coverage (bénéficiaire ou ayant droit) * having signed a specific written informed consent. Exclusion criteria of recipient and donor * Absence of written informed consent * Patient or donor on AME * Patient or donor on AME or under protection by law, tutorship or curatorship * Pregnant women
References
Publications (0)
Data not yet available